NCT03794037

Montelukast for Prevention & Treatment of OHSS

Montelukast for Prevention & Treatment of Ovarian Hyperstimulation Syndrome in Freeze-all Cycles

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Benha University · Academic / Other
• Sex: Female
• Age: 20 Years – 37 Years
• Healthy volunteers: Not accepted

Summary

montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Detailed description

patients with high risk for ovarian hyperstimulation will undergo a freeze-all protocol then montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Conditions

• Ovarian Hyperstimulation Syndrome

Interventions

Type	Name	Description
DRUG	dydrgesterone 10 mg( tab)/12hs/14 days	Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
COMBINATION_PRODUCT	montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days	montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&

Timeline

• Start date: 2018-12-05
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2019-01-04
• Last updated: 2022-09-21

Locations

1 site across 1 country: Egypt